Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.

MLA

Jeong, Woondong, et al. “Weekly EZN-2208 (PEGylated SN-38) in Combination with Bevacizumab in Patients with Refractory Solid Tumors.” Investigational New Drugs, vol. 32, no. 2, Apr. 2014, pp. 340–46. EBSCOhost, https://doi.org/10.1007/s10637-013-0048-3.

APA

Jeong, W., Park, S., Rapisarda, A., Fer, N., Kinders, R., Chen, A., Melillo, G., Turkbey, B., Steinberg, S., Choyke, P., Doroshow, J., & Kummar, S. (2014). Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. Investigational New Drugs, 32(2), 340–346. https://doi.org/10.1007/s10637-013-0048-3

Chicago

Jeong, Woondong, Sook Park, Annamaria Rapisarda, Nicole Fer, Robert Kinders, Alice Chen, Giovanni Melillo, et al. 2014. “Weekly EZN-2208 (PEGylated SN-38) in Combination with Bevacizumab in Patients with Refractory Solid Tumors.” Investigational New Drugs 32 (2): 340–46. doi:10.1007/s10637-013-0048-3.